Surgi-Vision Intercept
This article was originally published in The Gray Sheet
Executive Summary
Miniaturized MRI coil for prostate applications is launched at RSNA meeting following FDA 510(k) clearance. The coil will be distributed by GEMS, along with the previously cleared Intercept urethra and esophagus micro coils (1"The Gray Sheet" Oct. 30, 2000, p. 18). The firm also has a 510(k) pending for a vascular application of the Intercept. Clinical data presented at RSNA from an in vivo feasibility animal study sponsored by Surgi-Vision showed no complications observed using a 0.032 inch Intercept coil for intracoronary imaging, despite the coil staying in the target artery for 4-6 hours
You may also be interested in...
Surgi-Vision/GE Medical Will Market Internal MRI Coils In Early 2001
Surgi-Vision, Inc. plans to market internal magnetic resonance imaging (MRI) coils in the first quarter of 2001, following FDA 510(k) clearance of a MRI coil for insertion in the female urethra (SVUC) Oct. 11.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.